Skip to main content

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.